Medscape October 24, 2024
With the approval of anti-amyloid monoclonal antibodies to treat early-stage Alzheimer’s disease (AD), the need for accurate and early diagnosis is crucial.
Blood-based biomarkers offer a promising alternative to amyloid PET scans and cerebrospinal fluid (CSF) analysis and are being increasingly used in clinical practice to support an AD diagnosis.
Recently, an expert workgroup convened by the Global CEO Initiative on Alzheimer’s Disease published recommendations for the clinical implementation of AD blood-based biomarkers.
“Our hope was to provide some recommendations that clinicians could use to develop the best pathways for their clinical practice,” workgroup co-chair Michelle M. Mielke, PhD, with Wake Forest University School of Medicine, Winston-Salem, North Carolina, told Medscape Medical News.
Triage and Confirmatory Pathways
The group recommends...
Today's Sponsors
Today's Sponsor